Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Thomas Jefferson University
Takeda
H. Lee Moffitt Cancer Center and Research Institute
Penn State University
City of Hope Medical Center
Celgene
Dana-Farber Cancer Institute
Incyte Corporation
NextCure, Inc.
M.D. Anderson Cancer Center
Brown University
Acerta Pharma BV
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital
Servier
Novartis
Dana-Farber Cancer Institute
CRISPR Therapeutics
Incyte Corporation
Therapeutic Advances in Childhood Leukemia Consortium
Children's Oncology Group
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
AbbVie
Bristol-Myers Squibb
Bristol-Myers Squibb
Seattle Children's Hospital
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
Scripps Translational Science Institute
M.D. Anderson Cancer Center
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Celgene
City of Hope Medical Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
City of Hope Medical Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota